Abbonarsi

Prophylactic endoscopic coagulation to prevent delayed post-EMR bleeding in the colorectum: a prospective randomized controlled trial (with videos) - 18/10/19

Doi : 10.1016/j.gie.2019.05.039 
Hyun Seok Lee, MD, PhD 1, 2, Seong Woo Jeon, MD, PhD 1, 2, , Yong Hwan Kwon, MD, PhD 1, 2, Su Youn Nam, MD, PhD 2, Seonghwan Shin, MD 2, Ryanghi Kim, MD 2, Sohyun Ahn, MD 2
1 Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea 
2 Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea 

Reprint requests: Seong Woo Jeon, MD, PhD, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 807 Hoguk-ro, Buk-gu, Daegu, 41404, Korea.Department of Internal MedicineSchool of MedicineKyungpook National UniversityKyungpook National University Hospital807 Hoguk-ro, Buk-guDaeguKorea41404

Abstract

Background and Aims

Post-EMR bleeding (PEB) is the most common adverse event after EMR. However, there are no established endoscopic methods for the prevention of PEB. This study aimed to investigate whether prophylactic endoscopic coagulation (PEC) using coagulation probes reduces the incidence of overall delayed PEB.

Methods

We performed a randomized controlled study of patients undergoing EMR for large (≥10 mm) sessile lesions and laterally spreading tumors. Patients were randomized 1:1 to the EMR with coagulation group (n = 285) or EMR (control) group (n = 285). Immediate bleeding during colon EMR or clean-based ulcer after EMR was excluded. Clinically significant PEB was defined as bleeding requiring endoscopic hemostasis, hospitalization, or a decrease in the hemoglobin level >2 g/dL.

Results

A total of 569 patients were analyzed. The incidence of overall PEB was significantly lower in the EMR with coagulation group than in the control group (12.6% [36/285] vs 18.7% [53/284], P = .048). However, this was largely because of a reduction in minor bleeding. There was no difference in clinically significant PEB (1.8% [5/285] vs 3.2% [9/284], P = .276). Rectal location was a risk factor associated with overall PEB (odds ratio, 1.256; 95% confidence interval, 1.12-1.41; P < .001).

Conclusions

Although this study found reduced PEB with prophylactic cautery of visible vessels, this was largely because of a reduction in minor bleeding with no benefit observed for clinically significant bleeding. Overall, PEB was more frequent with rectal lesions. (Clinical trial registration number: KCT0000779.)

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : CI, OR, PEB, PEC


Mappa


 DISCLOSURE: The following author disclosed financial relationships relevant to this publication: S. W. Jeon: Major shareholder and CEO of Finemedix Co, Ltd. All other authors disclosed no financial relationships relevant to this publication.


© 2019  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 90 - N° 5

P. 813-822 - novembre 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • SIC-8000 versus hetastarch as a submucosal injection fluid for EMR: a randomized controlled trial
  • Douglas K. Rex, Heather M. Broadley, Jonathan R. Garcia, Rachel E. Lahr, Margaret E. MacPhail, Connor D. McWhinney, Meghan P. Searight, Andrew W. Sullivan, Neal Mahajan, George J. Eckert, Krishna C. Vemulapalli
| Articolo seguente Articolo seguente
  • Prevention is better than cure: the challenges of prophylactic therapy for post-EMR bleeding
  • W. Arnout van Hattem, Michael J. Bourke

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.